

**NINETY-SIXTH NATIONAL CONVENTION  
OF  
THE AMERICAN LEGION  
Charlotte, North Carolina  
August 26, 27, 28, 2014**

**Resolution No. 144: Prostate Cancer Research and Treatment**

**Origin: Maryland**

**Submitted by: Convention Committee on Veterans Affairs & Rehabilitation**

WHEREAS, Prostate cancer is the most common form of cancer, other than skin cancer, among men in the United States and is second only to lung cancer as a cause of cancer-related death among men; and

WHEREAS, One of six males will develop clinically significant prostate cancer in their lifetime; and

WHEREAS, The 2014 American Cancer Society Surveillance Research estimated that 233,000 new cases of prostate cancer will be diagnosed, while 29,480 will die within the next year; and

WHEREAS, Prostate cancer has been demonstrated to be service-connected to Agent Orange exposure and, pursuant to the Agent Orange Act of 1991, the Department of Veterans Affairs (VA) has determined that a presumption of service connection based on exposure to herbicides used in Vietnam is warranted for prostate cancer, in that VA has found a positive association between the condition and such exposure; and

WHEREAS, Advances in biomedical research are leading to new treatments and cures for all forms of cancer, and will lower long-term health care costs; and

WHEREAS, VA is very productive in advancing medical knowledge, improving health care for veterans and all other citizens; now, therefore, be it

**RESOLVED, By The American Legion in National Convention assembled in Charlotte, North Carolina, August 26, 27, 28, 2014, That federal funding for prostate cancer research, treatment, and therapies at the National Institutes of Health, Department of Defense, and Department of Veterans Affairs (VA) be significantly increased and that Congress and the Administration re-double their efforts to find a cure for prostate cancer; and, be it finally**

**RESOLVED, That the Veterans Health Administration increase its investment in prostate cancer clinical research by improving and accelerating clinical trials at VA hospitals and affiliated university medical centers and research programs.**